The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

GlaxoSmithKline, Theravance start Phase III trial of fluticasone furoate/vilanterol to treat COPD.....           Valeant, Ackman sign deal to acquire Botox-maker Allergan for $45bn.....           Pfizer may push ahead with second approach for AstraZeneca?s deal.....           Biodel announces collaboration agreement With HEC Pharm.....           Bayer's Ciprofloxacin DPI gets FDA orphan drug designation.....           Vascular Solutions enters into agreement with US Army to develop freeze-dried plasma product.....           Elsevier and Russia's Ural Federal University sign license agreement for Pure.....           Elite Pharmaceuticals granted new patent for Abuse Deterrent technology.....           Amgen's $4.5B in Q1 sales lags estimates, thanks to slow-selling Enbrel.....           Novartis reshapes business by signing deals with GSK, Eli Lilly.....           Sagent reintroduces Adenosine injection with improved prefilled plastic syringes.....           Biogen Idec exercises option with Amunix to develop XTENylated Factor VIII products.....           FDA grants orphan drug designation to Emergent's anthrax vaccine BioThrax.....           GlaxoSmithKline and Novartis, starring players in a Big Pharma deal bonanza.....           Eli Lilly's Elanco snags Novartis' animal health unit in $5.4B deal.....           $16B deal for GlaxoSmithKline oncology meds turns Novartis into cancer heavyweight.....           GlaxoSmithKline pledges $7.1B to add Novartis vaccines to its leading lineup.....           Novartis, GSK team up in consumer JV to save big money, gain big scale.....           Pfizer to plunk down $190M to wrap up Neurontin class action.....           Valeant touts quick cost cuts in $45B hostile bid for Allergan.....           Gilead's Sovaldi turns in outsize Q1 sales.....           FDA approves Lilly's CYRAMZA to treat advanced gastric cancer.....           Foamix announces issuance of five additional US patents.....           Enzymotec announces final decision issued by USPTO rejecting all claims in Neptune's patent.....           BioCision's temperature standardization technology to be used in TxCell Phase IIb cell therapy clinical trial.....           ProNAi Therapeutics raises $59.5m Series D financing.....           CTCA selects Medline as prime vendor distribution partner for medical and surgical supplies.....           Cubist seeks FDA approval for new antibiotic to treat cUTI and cIAI.....           Regenerx gets notice of allowance for US patent for treatment of stroke using T4.....           Coldstream Laboratories completes successful FDA inspection.....           Kyowa Hakko Kirin announces termination of Mogamulizumab licensing agreement with Amgen.....           Boehringer Ingelheim receives orphan drug designation for volasertib in US and EU.....           NanoValent, NanoSmart to develop enhanced cancer pharmaceuticals.....           Alcresta announces agreement with CFFT to develop point-of-care nutritional products.....           Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay.....           Bulk up or slim down? Maybe both: Pfizer said to weigh a $100B deal for AstraZeneca.....           Report: Biopharma CEOs score 'supersalaries' even as sales decline.....           AbbVie careful about gay rights in its discussion of a new trial.....           The price is right for patient-switching on Biogen's new hemophilia med Alprolix.....           Docs that just say no to drug samples slash brand prescribing big-time, study finds.....           GSK obtains Canadian approval for Incruse Ellipta.....           VentiRx Pharmaceuticals completes patient enrollment in Phase II GOG-3003 study.....           Akorn closes Hi-Tech Pharmacal?s acquisition.....           Agios Pharmaceuticals begins Phase I study of pyruvate kinase deficiency drug.....           Cubist Pharmaceuticals initiates voluntary recall of Cubicin intravenous injection.....           MultiCorp engages two firms to develop clinical trial procedures on patented migraine medicine.....           XBiotech announces Phase I/II study results in Lancet Oncology.....           FDA, European Commission grant orphan drug status to Boehringer's volasertib.....           Astellas, MSD launch Suglat tablets in Japan to treat type 2 diabetes.....           OxThera secures $10m investment to continue clinical programs.....           Kyowa Hakko begins Phase III trial of asthma drug benralizumab in Japan.....           Islet Sciences reports results from two Phase IIb clinical studies for type 2 diabetics drug.....           Impax introduces Renvela for patients with chronic kidney disease.....           Pharma's top 10 M&A deals of 2013.....           Under fire from local pharmas, China backs off price caps.....           GlaxoSmithKline steps up bribery probes, eyeing potential violations in 9 Middle Eastern countries.....           Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says.....           England sets aside $31M to fund Sovaldi for sickest patients.....           Novartis near to wrapping up $1.7B sale of part-owned patchmaker LTS Lohmann.....           Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture.....           Dicerna begins Phase I trial of DCR-MYC to treat solid tumors, hematological malignancies.....           AMRI realigns discovery and development services to support customer demand.....           European Medicines Agency alerts EU healthcare professionals after vials of falsified Herceptin identified.....           Astellas Pharma reaches agreement with US Department of Justice.....           Apricus Biosciences' UK partner accepts first shipment of Vitaros.....           Iconic Therapeutics raises $20m to advance clinical development of wet AMD program.....           Top 10 M&A deals of 2013.....           Medac Pharma gets FDA approval for trade name Rasuvo for injectable MTX product.....           Prosonix, Mylan license agreement for generic versions of Flixotide and Flovent.....           RainTree launches new cloud-based analytics portal for pharmaceutical industry.....           Prestige to acquire OTC oral rehydration product Hydralyte in Australia.....           DesignMedix gets $3m NIH grant to develop low-cost malaria drug.....           Amgen's Bradway nets $13.65M in 2013, sans Onyx bonus.....           Reckitt CFO: Spinoff of pharma unit a 'strong option'.....           New report finds Bydureon safest of new class of diabetes drugs.....           EMA warns Herceptin vials stolen in Italy spreading through EU.....           GlaxoSmithKline's new diabetes med faces formidable GLP-1 foes.....           Judge halts Massachusetts governor's ban on powerful Zogenix painkiller.....           GlaxoSmithKline's Tanzeum gets FDA approval for type 2 diabetes treatment.....           Actavis announces agreement related to Generess FE patent challenge litigation.....           PanOptica raises $45m to finance clinical development of anti-VEGF eye drop for wet AMD.....           Sanofi launches Probi Digestis in Korea.....           Kineta and RLB Holdings announce new joint venture.....           Akebia Therapeutics completes enrollment in its Phase IIb clinical study of AKB-6548.....           IntelliCell BioSciences selects inVentiv Health Clinical as CRO for osteoarthritis IND.....           Moberg Pharma to acquire global rights of bupivacaine from Oracain.....           FDA extends market exclusivity of BioMarin's Phenylketonuria drug Kuvan for six months.....           FDA accepts NDA for combination drug to treat type 2 diabetes.....           BMV Medica to distribute Easton's Viorra in Mexico.....           Roche cancer drugs Perjeta and Kadcyla drive strong Q1 results.....           Novartis marks 235 admin jobs for deletion amid companywide restructuring.....           New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast.....           Boehringer Ingelheim revenue slide cushioned by Pradaxa sales jump.....           Novartis' gain is consumers' $900M loss from stalled Ranbaxy generics.....           Generics makers ask SCOTUS to let them proceed with Copaxone copies.....           BMS files NDA to FDA for combination tablet to treat HIV-1.....           Advaxis announces notice of allowance for two patent applications in Japan.....           Depomed announces settlements with two Gralise ANDA filers.....           Mast Therapeutics announces new data supporting MST-188 in sickle cell disease.....           Surrey Clinical Research Centre signs five year agreement for OmniComm Systems' Promasys.....           ProTrials completes significant Phase III clinical trial for new ophthalmic disease treatment.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists
Latest News
The APS launches its new Parenterals Focus Group
The APS would like to announce the launch of its new Parenterals Focus Group. The group will provide a network for those interested in the science and technology of parenteral products and will aim to raise the profile of parenteral product development in the UK by stimulating scientific collaborations and providing a forum for information sharing and discussion of ‘hot topics’.. The group are interested in all aspects of parenteral product development but the steering committee have identified the following three themes to shape their initial programme over the coming year.. Meeting the needs of the user (medics, pharmacists, nurses and patients) – addressing current issues and preparing for the patient and products of the future. Alternative drying technologies for biotherapeutics and small molecules (in collaboration with the Biotherapeutics FG) . Challenges with the administration of parenteral products (‘in-use’ stability, giving set compatibility, interactions with co‑medications etc.) . The launch event for the Parenterals group will take place at this year’s UKPharmSci meeting in September. The group will be hosting a session on the afternoon of Tuesday September 9th entitled:. ‘Parenteral Drug Development: The Challenges of Adapting to Changing Patient Needs’ . During this session we will explore how the pharma industry can respond to the needs of the future, both in terms of the delivery of new types of parenteral medications, such as nanomedicines, as well as the ways in which parenteral products are administered e.g. home administration. The event will conclude with a roundtable discussion which we hope will help drive the future agenda of the group.. We are also planning a joint event with the Therapeutic Vaccines and Biologics Focus group – watch this space for further details.. You can stay up to date with the Parenterals Focus group developments by subscribing to our focus group from the ‘my account’ tab of the APS web-page. If you are interested in joining the steering committee, please contact Jo Broadhead or Jo Simmons by using the contact button on our focus group web-page..
APS launch new Microbiology & Anti-Infectives Focus Group
The APS would like to announce the launch of its new Microbiology and Anti-infectives Focus Group. Details on its mission and how to get involved are given below:. . Scope . The Microbiology and Anti-infectives focus group is being launched in 2014 to provide a forum for the promotion of pharmaceutical microbiology and anti-infectives research and development within the academic, regulatory and industrial pharmaceutical sciences. The focus group is open to all members with an interest in pharmaceutical microbiology, antibiotic resistance, anti-infectives research and development, antibiotic innovation and regulatory developments. . . The main aims of this focus group are:. . To provide a forum for discussion of all aspects of pharmaceutical microbiology and anti-infectives research and development, that are of interest to members of the APS Seek to raise the profile of pharmaceutical microbiology and anti-infectives research across the pharmaceutical and allied sciences To underpin the importance of microbiology to the pharmaceutical sciences and innovation Collaborate and coordinate with other relevant organisations active in the field Provide continuing education for the membership, through annual symposia and focused meetings . Launch meeting. An initial meeting of the Microbiology & Anti-infectives focus group is planned for May 19th, School of Pharmacy, Queen’s University Belfast. At this meeting we will identify and prioritise the main areas of interest for the focus group with a view to organising an ongoing programme of 1-2 day meetings. At this meeting a steering group will be formed to develop the ongoing themes of the focus group activities.. . A programme is currently under development for PharmSci 2014 (8th – 10th September 2014, University of Hertfordshire); please consider submitting your abstracts for oral/poster presentations. Wiley-Blackwell have kindly agreed to sponsor a prize for the best poster in the Pharmaceutical Microbiology category, the winner will receive £100 and a copy of Hugo & Russell’s Pharmaceutical Microbiology 8th Edition.. . If you are interested in attending the launch meeting, becoming involved in the steering committee or joining the Microbiology & Anti-infectives Focus Group, please contact Brendan Gilmore via the FG website at the following link:. .
Progress within the IMI OrBiTo project
Predictive tools for oral biopharmaceutics GSK, Stevenage Tuesday 13th May 2014 The Innovative Medicines Initiative (IMI) ORBITO project is a pre-competitive collaboration between pharma, academia and specialist technology companies which aims to enhance our understanding of how orally-administered drugs are absorbed from the gastrointestinal tract and apply this knowledge to develop new in vitro tests and in silico models that will better predict the performance of oral formulations in patients ( The OrBiTo project started in October 2012 and this is the first open meeting at which key progress will be shared with the wider scientific community. Professor Gordon Amidon will also present an update from his on-going research programme on assessing the bioperformance of oral drug products. This meeting is aimed at industrial and academic scientists working in the areas of biopharmaceutics, formulation design, regulatory CMC and analytical development. Scientists who are new to the area will also find the meeting useful for gaining a broad understanding of the key scientific and technical issues relevant to oral biopharmaceutics. Poster presentations are welcomed from all attendees. For more information, please visit us online at:
Skin Forum 2014, September 4th and 5th, Prague, Czech Republic.
. The final programme and registration forms for this year's joint Skin Forum - APV meeting are now available on the APV website at the following links: . . Programme and Fees. . . Abstract Submission. . . Programme and Fees. . This year's programme features a dedicated industrial transdermal formulation session. For any queries related to the meeting please contact: . . . . . . . .
Follow us
Upcoming Events
APS Amorphous by Design 2014
28 - 29 April 2014
Progress within the IMI OrBiTo project predictive tools for oral biopharmaceutics
13 May 2014
APS Board Meeting
8 - 9 July 2014
APS PharmSci 2014
8 - 10 September 2014
APS Board Meeting
14 - 15 October 2014
View all Vacancies
Advertise your job vacancies
Following the extensive news coverage of the Heartbleed attack the Academy can confirm that it has NOT been affected and usernames and password used on this site have NOT been compromised.
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.